Medical Devices

With backing from GV and Dexcom, Signos is using AI and OTC glucose monitors to offer a new path for sustainable weight management beyond GLP-1 drugs.

The cold storage giant's strategic acquisition of a pharma-certified specialist signals a major shift into the high-stakes world of medical logistics.

With late-stage trials for its revolutionary eye and lung disease treatments, 4DMT must convince investors its focused, high-stakes strategy will pay off.

New preclinical data shows RTY-406 could be a first-in-class therapy for PSC, a progressive liver disease with no effective treatments.

Vanda Pharmaceuticals' rare disease drug gets a key designation in Japan, unlocking major incentives and promising a new treatment for a severe skin disease.

A major merger backed by US private equity creates a new powerhouse in Romania's complex care market, raising questions about access and physician roles.

Ionetix wins FDA approval for its generic prostate cancer imaging agent, a move set to boost access and shake up the competitive radiopharmaceutical market.

Following its X3D acquisition, Catalyst MedTech unveils an expanded portfolio and a new strategy to tackle aging equipment and modernize nuclear medicine.

DePuy Synthes acquires novel radiofrequency tracking to move beyond the line-of-sight limits and invasive pins of current robotic joint surgery systems.

A Chinese firm services ultrasound machines in 140+ countries, challenging OEM dominance and helping hospitals cut costs and extend equipment life.

A new report reveals Europe's medically-focused cannabis market is finally waking, creating a new global blueprint but also intense competition and price wars.

A breakthrough 'pap smear for the pancreas' that detects early cancer has secured major funding, offering new hope against one of the deadliest diseases.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

A skincare brand is challenging the FDA over sunscreen ingredients, revealing decades of regulatory delay and raising questions about what’s safe for our skin.

With strong clinical data for its Dayspring system, Koya Medical is pitching to investors to fund the next phase of growth for its patient-centered tech.

Growth equity firm AVANT BIO adds biomanufacturing legends Maik Jornitz and Lukas Utiger, signaling a shift toward deep operational support for its startups.

A landmark Novo Nordisk study finds 2 in 5 heart patients have hidden inflammation, a major risk for heart attack and stroke despite standard treatments.

With game-changing Phase III data for iza-bren in breast cancer and a deep pipeline, SystImmune is poised to make a major impact at ASCO 2026.

On the sidelines of the World Health Assembly, three startups won major funding for AI tools that predict outbreaks, find cancer, and empower health workers.

Caliway Biopharma advances its fat-loss drug, promising objective, MRI-verified results in a market hungry for safer, more reliable aesthetic options.